Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
December 19, 2024
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk® Hereditary Cancer Test with RiskScore® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute.
The study by Mabey et al., “Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors,” presented a longitudinal clinical validation of MyRisk with RiskScore using data from more than 130,000 women referred for hereditary cancer genetic testing.
RiskScore integrates a polygenic risk score (PRS) for all ancestries with the widely used Tyrer-Cuzick model. The study demonstrated that Myriad’s PRS is a more accurate predictor of breast cancer risk than Tyrer-Cuzick alone. In fact, RiskScore delivered two times the ability to predict breast cancer risk than the Tyrer-Cuzick model. Additionally, Myriad was one of the first commercial laboratories to market with a multi-ancestry breast-cancer PRS, driven by its mission to advance health equity and deliver more inclusive genetic insights.
“We are honored by this recognition, which underscores the clinical significance of the validation research from the study and predictive accuracy of RiskScore,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “MyRisk with RiskScore can assist both clinicians and patients in making informed, proactive medical management decisions to help prevent breast cancer or detect it early. The accuracy of RiskScore across all ancestries emphasizes Myriad’s commitment and contribution to health equity.”
“We hope that the selection of our paper as a major advance will continue to drive the adoption of RiskScore by providers and guideline societies,” continued Muzzey.
About MyRisk® Hereditary Cancer Test with RiskScore®
MyRisk Hereditary Cancer Test with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that MyRisk with RiskScore being featured as a top innovation in genomic medicine reinforces the need for more wide-scale clinical implementation of MyRisk with RiskScore, as this data is likely to have implications for healthcare systems and practice guidelines, and MyRisk with RiskScore can assist both clinicians and patients in making informed, proactive medical management decisions to help prevent breast cancer or detect it early. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com